Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide

被引:43
|
作者
Campian, Jian L. [1 ]
Piotrowski, Anna F. [2 ]
Ye, Xiaobu [3 ]
Hakim, Frances T. [4 ]
Rose, Jeremy [4 ]
Yan, Xiao-Yi [4 ]
Lu, Yao [5 ]
Gress, Ronald [4 ]
Grossman, Stuart A. [3 ]
机构
[1] Washington Univ, Div Oncol, Dept Med, St Louis, MO 63110 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10065 USA
[3] Johns Hopkins Univ, Dept Oncol, Sch Med, Baltimore, MD 21287 USA
[4] NCI, Preclin Dev & Clin Monitoring Facil, Expt Transplantat & Immunol Branch, Bethesda, MD 20892 USA
[5] Cornell Univ, Ithaca, NY 14850 USA
基金
美国国家卫生研究院;
关键词
High grade astrocytoma; Lymphopenia; Radiation; Temozolomide; Lymphocyte subsets; TREATMENT-RELATED LYMPHOPENIA; CELL LUNG-CANCER; EXTRACORPOREAL IRRADIATION; ADVANCED MELANOMA; SURVIVAL; ASSOCIATION; GLIOMAS; GLIOBLASTOMA; CHEMOTHERAPY; TUMORS;
D O I
10.1007/s11060-017-2580-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The immune system plays a significant role in cancer prevention and outcome. In high grade astrocytomas (HGA), severe lymphopenia is associated with shortened survival due to tumor progression. This study was performed to quantify serial changes in lymphocyte subsets in HGA following standard radiation (RT) and temozolomide (TMZ). Adults (KPS > 60, HIV negative) with newly diagnosed HGA scheduled to receive concurrent RT and TMZ and adjuvant TMZ were eligible. Blood was collected before beginning concurrent RT/TMZ and at weeks 6, 10, 18, and 26, and 3 months after completing adjuvant TMZ. Lymphocyte subsets were analyzed by flow cytometry. Twenty patients (70% glioblastoma, median age 53, 50% male, 80% Caucasian) who enrolled from January 2014 to August 2014 were followed until April 2016. Baseline dexamethasone dose was 0.5 mg/day and 15% had absolute lymphocyte counts (ALC) < 1000 cells/mm(3) before starting RT/TMZ. However, 75% developed lymphopenia with ALC < 1000 cells/mm(3) after completion of RT/TMZ. NK cells, B cells and all T lymphocytes subsets dropped significantly after concurrent RT/TMZ and remained depressed for the 48 weeks of observation. The CD4+/CD8+ ratio was not affected significantly during follow-up. Severe lymphopenia involving all subsets occurred early in treatment and remained present for nearly 1 year. To our knowledge, this is the first report of serial trends in lymphocyte subsets following standard RT and TMZ for HGA.
引用
收藏
页码:343 / 351
页数:9
相关论文
共 50 条
  • [1] Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide
    Jian L. Campian
    Anna F. Piotrowski
    Xiaobu Ye
    Frances T. Hakim
    Jeremy Rose
    Xiao-Yi Yan
    Yao Lu
    Ronald Gress
    Stuart A. Grossman
    Journal of Neuro-Oncology, 2017, 135 : 343 - 351
  • [2] Serial evaluation of lymphocyte subsets in patients with newly diagnosed high grade gliomas treated with standard radiation and temozolomide
    Piotrowski, Anna F.
    Campian, Jian Li
    Hakim, Frances
    Rose, Jeremy
    Yan, Xiao-Yi
    Gress, Ronald
    Grossman, Stuart A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Effect of standard therapy on lymphocyte subsets and cytokines in newly diagnosed high-grade gliomas (HGG).
    Balmanoukian, A. S.
    Grossman, S. A.
    Thoburn, C.
    Kos, F.
    Holdhoff, M.
    Hess, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE
    Ly, Ina
    Cardona, Jonathan
    Beers, Andrew
    Chang, Ken
    Brown, James
    Reardon, David
    Arrillaga-Romany, Isabel
    Dietrich, Jorg
    Forst, Deborah
    Lee, Eudocia
    Jordan, Justin
    Nayak, Lakshmi
    Wen, Patrick
    Batchelor, Tracy
    Kalpathy-Cramer, Jayashree
    Gerstner, Elizabeth
    NEURO-ONCOLOGY, 2018, 20 : 191 - 191
  • [5] MRI changes in patients with newly diagnosed glioblastoma treated as part a Phase II trial with bavituximab, radiation, and temozolomide
    Ly, Ina
    Cardona, Jonathan
    Beers, Andrew
    Chang, Ken
    Brown, James
    Reardon, David
    Arrillaga-Romany, Isabel
    Dietrich, Jorg
    Forst, Deborah
    Lee, Eudocia
    Jordan, Justin
    Nayak, Lakshmi
    Wen, Patrick
    Batchelor, Tracy
    Curry, William
    Kalpathy-Cramer, Jayashree
    Gerstner, Elizabeth
    NEUROLOGY, 2019, 92 (15)
  • [6] CYTOPENIAS IN PATIENTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMAS RECEIVING RADIATION AND TEMOZOLOMIDE-WHO IS AT RISK?
    Mrugala, M. M.
    Johnston, S. K.
    Chamberlain, M. C.
    San, J. V.
    Rockhill, J. K.
    Haug, J.
    Spence, A. M.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1120 - 1120
  • [7] Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma
    Narayana, Ashwatha
    Golfinos, John G.
    Fischer, Ingeborg
    Raza, Shahzad
    Kelly, Patrick
    Parker, Erik
    Knopp, Edmond A.
    Medabalmi, Praveen
    Zagzag, David
    Eagan, Patricia
    Gruber, Michael L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (02): : 383 - 389
  • [8] The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas
    Gerber, David E.
    Grossman, Stuart A.
    Zeltzman, Michel
    Parisi, Michele A.
    Kleinberg, Lawrence
    NEURO-ONCOLOGY, 2007, 9 (01) : 47 - 52
  • [9] Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas
    Jian L. Campian
    Xiaobu Ye
    Douglas E. Gladstone
    Prakash Ambady
    Thomas R. Nirschl
    Ivan Borrello
    Marc Golightly
    Karen E. King
    Matthias Holdhoff
    Judith Karp
    Charles G. Drake
    Stuart A. Grossman
    Journal of Neuro-Oncology, 2015, 124 : 307 - 316
  • [10] Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas
    Campian, Jian L.
    Ye, Xiaobu
    Gladstone, Douglas E.
    Ambady, Prakash
    Nirschl, Thomas R.
    Borrello, Ivan
    Golightly, Marc
    King, Karen E.
    Holdhoff, Matthias
    Karp, Judith
    Drake, Charles G.
    Grossman, Stuart A.
    JOURNAL OF NEURO-ONCOLOGY, 2015, 124 (02) : 307 - 316